

BIOSIGN TO ACQUIRE ASSETS OF HEALTHANYWHERE INC.

TORONTO, ONTARIO, Monday, October 4, 2010 – Biosign Technologies Inc. (“Biosign”) (**TSXV: BIO**) has entered into a binding letter of intent to purchase assets of Healthanywhere Inc. (“HA”), a privately held eHealth solutions provider. The purchase price of \$4.3 million is to be satisfied by the issuance of 3.5 million common shares of Biosign. Completion of the transaction is conditional upon negotiation of a definitive asset purchase agreement and approval from TSX Venture Exchange. The transaction is expected to close on or about October 12, 2010.

HA provides software solutions addressing the continuum of care from wellness promotion and self-managed care to chronic disease management, particularly hypertension, diabetes, congestive heart failure, asthma, obesity, and mental disorders. The solutions can help improve quality of life, encourage compliance, protect privacy, and provide positive clinical outcomes. They are tried, tested, and certified for sale in Canada and the United States as medical devices. Biosign could use HA software as an immediate platform for providing unique services for cardiovascular risk assessment, medication optimization, and adverse event monitoring.

HA’s platform consists of:

- “Health On The GO” – a mobile platform for smartphone and PDA that acts as a personal telehealth assistant for monitoring vital signs; it includes advanced features such as calendars, reminders and questionnaires are effective tools to track, manage and promote adherence to individual care plans;
- “Health at Home” – a chronic disease management platform with a user friendly graphical interface available on touch screen technology. The platform can be installed on a variety of non-proprietary hardware (PC, netbook or Tablet PC) to provide a rich user environment for data capture, access to educational or nutritional content and interactive healthcare information exchange between patients and providers;
- “Health Assist” – a portable mobile health (mHealth) kiosk. Health Assist is designed for Healthcare Agencies and Service Providers, Community Care Providers, Screening, Telehome Care, At-Risk Patients, General Wellness and Preventative Care;
- “Health Station” – a site-based health management kiosk installable at specialized locations. It provides users secure access to their patient profile with the ability to capture vital sign data into their personal health record and to view pertinent nutritional or educational content. This platform is well adapted for screening and early detection, assessment, and wellness promotion, in either highly visible or discrete locations. It may be configured for two-way video capability.

In addition, HA has developed two Health Portals with online access to a secure website to view patient/user data and to facilitate health management by professionals and individual users. The Healthcare Professional Portal is HIPAA and HL-7 compliant. The entire platform has received FDA 510k clearance as a class II medical device.

Radu Leca, Biosign’s CEO, noted: “HA has a comprehensive solution for disease and patient management. We want to integrate it with our measurement system to complete our unique offer: a trusted health information system anyone could use to evaluate and manage their health: online, anytime... anywhere indeed.”

Contact Information

Alan S. Roemer, SVP
The Trout Group LLC
Phone: 646 378-2900
Email : aroemer@troutgroup.com

Radu Leca, President & CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
Email: ceo@biosign.com

About Biosign Technologies Inc.

Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com.

About Healthanywhere Inc.

We focus on providing hardware agnostic technologies applied throughout the continuum of care to enable improved health and wellness. Our innovative approach and experienced market knowledge ensure that we remain at the forefront of eHealth application providers and integrators. Healthanywhere's collective resources represent many years of industry leading experience. Our unique eHealth & mHealth patient centric solutions, applied to prevention, pre-acute and post-acute patient care models, facilitate remote and interactive monitoring to better manage chronic disease conditions, and to promote wellness and well-being. Healthanywhere is a private company based in Mississauga Ontario. Additional information can be found at www.healthanywhere.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."